Hemoglobinuria

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Markets 2017-2018 & 2019-2025 - ResearchAndMarkets.com

Retrieved on: 
Mardi, juillet 16, 2019
Health, Pharmaceutical, PNH, Paroxysmal nocturnal hemoglobinuria, Paroxysmal attack, Hemoglobinuria, Medicine, Clinical medicine, Ham test, Paroxysmal hemoglobinuria

The "Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The report predicts the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market to grow with a CAGR of 11.6% over the forecast period from 2019-2025.
  • The report on the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market provides qualitative and quantitative analysis for the period from 2017 to 2025.
  • The report on paroxysmal nocturnal hemoglobinuria (PNH) treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market over the period of 2017 to 2025.

Global paroxysmal nocturnal hemoglobinuria (PNH) treatment market is expected to grow with a CAGR of 11.6% over the forecast period from 2019-2025

Retrieved on: 
Mercredi, juin 26, 2019
PNH, Paroxysmal nocturnal hemoglobinuria, Paroxysmal attack, Hemoglobinuria, Medicine, Clinical medicine, Ham test, Paroxysmal hemoglobinuria

NEW YORK, June 26, 2019 /PRNewswire/ -- The report on the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market provides qualitative and quantitative analysis for the period from 2017 to 2025.

Key Points: 
  • NEW YORK, June 26, 2019 /PRNewswire/ -- The report on the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market provides qualitative and quantitative analysis for the period from 2017 to 2025.
  • The report predicts the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market to grow with a CAGR of 11.6% over the forecast period from 2019-2025.
  • The study on paroxysmal nocturnal hemoglobinuria (PNH) treatment market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.
  • The report on paroxysmal nocturnal hemoglobinuria (PNH) treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market over the period of 2017 to 2025.

ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Retrieved on: 
Mardi, juin 18, 2019
Health, Cardiology, Clinical trials, Pharmaceutical, Other Health, Bacteria, Medicine, Medical specialties, Blood disorders, Atypical hemolytic uremic syndrome, Syndromes, Acquired hemolytic anemia, PNH, Paroxysmal nocturnal hemoglobinuria, Paroxysmal attack, Hemoglobinuria, Neisseria meningitidis

The Phase 3 study of ULTOMIRIS, administered intravenously every eight weeks in adult patients with aHUS, met its primary objective .

Key Points: 
  • The Phase 3 study of ULTOMIRIS, administered intravenously every eight weeks in adult patients with aHUS, met its primary objective .
  • ULTOMIRIS is also currently being evaluated in a Phase 3 clinical study in children and adolescents with aHUS, administered intravenously every eight weeks.
  • ULTOMIRIS is used to treat adults with a disease called paroxysmal nocturnal hemoglobinuria (PNH).
  • If ones doctor decided that urgent treatment with ULTOMIRIS is needed, meningococcal vaccination should be administered as soon as possible.

Global Paroxysmal Nocturnal Hemoglobinuria Clinical Trial Pipeline Highlights, 2019 - ResearchAndMarkets.com

Retrieved on: 
Lundi, juin 10, 2019
Health, Clinical trials, Pharmaceutical, Health, Clinical research, Design of experiments, Clinical trial, Drug discovery, Pharmaceutical industry, Hemoglobinuria, Paroxysmal attack, Paroxysmal hemoglobinuria

The "Global Paroxysmal Nocturnal Hemoglobinuria Clinical Trial Pipeline Highlights, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Paroxysmal Nocturnal Hemoglobinuria Clinical Trial Pipeline Highlights, 2019" report has been added to ResearchAndMarkets.com's offering.
  • This report provides most up-to-date information on key pipeline products in the global Paroxysmal Nocturnal Hemoglobinuria market.
  • It covers emerging therapies for Paroxysmal Nocturnal Hemoglobinuria in active clinical development stages including early and late stage clinical trials.
  • The report provides Paroxysmal Nocturnal Hemoglobinuria pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

PNH Treatment Market Size Worth $5.8 Billion by 2025 | CAGR: 11.2%: Grand View Research, Inc.

Retrieved on: 
Lundi, juin 10, 2019
Organ systems, Medicine, PNH, Paroxysmal nocturnal hemoglobinuria, Clinical medicine, Hemoglobinuria, Paroxysmal attack, Hematologic disease, Hematopathology, Ham test, Eculizumab

Apart from drugs, the stem cell transplant segment is projected to witness double-digit growth through the forecast period

Key Points: 
  • Apart from drugs, the stem cell transplant segment is projected to witness double-digit growth through the forecast period
    Currently, 16 products are under clinical evaluation for PNH treatment in various stages of development.
  • Promising pipeline candidates such as ALXN1210, Coversin, APL2, and RA101495 offer significant commercial potential post regulatory approval.
  • Read 65 page research report with TOC on "Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Transplant, Blood Transfusion), And Segment Forecasts, 2018 - 2025" at: https://www.grandviewresearch.com/industry-analysis/paroxysmal-nocturnal...
    Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder.
  • Grand View Research has segmented the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market based on treatment and major markets:
    Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Outlook (Revenue, USD Million; 2017 - 2025)

PNH Treatment Market Size Worth $5.8 Billion by 2025 | CAGR: 11.2%: Grand View Research, Inc.

Retrieved on: 
Lundi, juin 10, 2019
Organ systems, Medicine, PNH, Paroxysmal nocturnal hemoglobinuria, Clinical medicine, Hemoglobinuria, Paroxysmal attack, Hematologic disease, Hematopathology, Ham test, Eculizumab

Apart from drugs, the stem cell transplant segment is projected to witness double-digit growth through the forecast period

Key Points: 
  • Apart from drugs, the stem cell transplant segment is projected to witness double-digit growth through the forecast period
    Currently, 16 products are under clinical evaluation for PNH treatment in various stages of development.
  • Promising pipeline candidates such as ALXN1210, Coversin, APL2, and RA101495 offer significant commercial potential post regulatory approval.
  • Read 65 page research report with TOC on "Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Transplant, Blood Transfusion), And Segment Forecasts, 2018 - 2025" at: https://www.grandviewresearch.com/industry-analysis/paroxysmal-nocturnal...
    Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder.
  • Grand View Research has segmented the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market based on treatment and major markets:
    Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Outlook (Revenue, USD Million; 2017 - 2025)

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Mercredi, mai 8, 2019
Health, Pharmaceutical, Acquired hemolytic anemia, Rare diseases, Hemoglobinuria, Paroxysmal attack, Paroxysmal nocturnal hemoglobinuria, Medicine, Clinical medicine, Paroxysmal hemoglobinuria

The "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Paroxysmal Nocturnal Hemoglobinuria development.
  • The report covers pipeline activity across the complete product development cycle i.e.
  • clinical, pre-clinical and discovery stages for Paroxysmal Nocturnal Hemoglobinuria
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Paroxysmal Nocturnal Hemoglobinuria
    Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Retrieved on: 
Vendredi, avril 26, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, General Health, Organ systems, Medicine, Rare diseases, Medical specialties, Acquired hemolytic anemia, Paroxysmal nocturnal hemoglobinuria, Atypical hemolytic uremic syndrome, PNH, Paroxysmal attack, Complement system, Hemoglobinuria, Eculizumab

Regulatory authorities in Japan are reviewing Alexions application for the approval of ULTOMIRIS as a treatment for patients with PNH.

Key Points: 
  • Regulatory authorities in Japan are reviewing Alexions application for the approval of ULTOMIRIS as a treatment for patients with PNH.
  • ULTOMIRIS works by inhibiting the C5 protein in the terminal complement cascade, a part of the bodys immune system.
  • The Phase 3 study of ULTOMIRIS, administered intravenously every eight weeks in adult patients with aHUS, met its primary objective .
  • ULTOMIRIS is used to treat adults with a disease called paroxysmal nocturnal hemoglobinuria (PNH).

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market 2017-2025 - Wider adoption of Novel Therapeutics, and Emergence of Biologics are Driving the Market

Retrieved on: 
Mardi, novembre 20, 2018
Medicine, Acquired hemolytic anemia, Blood disorders, PNH, Paroxysmal nocturnal hemoglobinuria, Clinical medicine, Hemoglobinuria, Paroxysmal attack, Hematologic disease, Hematopathology, Ham test

The "Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Transplant, Blood Transfusion), And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Transplant, Blood Transfusion), And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 5.8 billion by 2025 at a 11.2% CAGR during the forecast period.
  • Several factors such as rise in number of blood and bone marrow related disorders, increase in geriatric population, wider adoption of novel therapeutics, and emergence of biologics are driving the market.
  • Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder.

The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 5.8 billion by 2025 at a 11.2% CAGR during the forecast period

Retrieved on: 
Mercredi, novembre 14, 2018
Hematology, Medicine, Hematopathology, Blood disorders, Acquired hemolytic anemia, Blood, Rare diseases, Paroxysmal nocturnal hemoglobinuria, Hemolytic anemia, Pancytopenia, PNH, Hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder.It is an ultra-rare disease with approximately 8,000 to 10,000 cases reported in North America and Europe.

Key Points: 
  • Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder.It is an ultra-rare disease with approximately 8,000 to 10,000 cases reported in North America and Europe.
  • The life-threatening disease often manifests in three forms: thrombosis, persistent intravascular hemolysis, and pancytopenia.
  • Blood transfusion and supportive care are anticipated to lose momentum during the forecast period due to adverse side effects and sub-optimal efficacy.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.